

## Special Issue

# New Strategies for Molecular Targeted Therapy in Multiple Myeloma

### Message from the Guest Editor

This Special Issue will gather cutting-edge research exploring innovative molecular targets and therapeutic strategies to overcome current limitations and improve patient outcomes. Topics of interest include, but are not limited to, the following:

- Novel drug targets and signaling pathways in multiple myeloma;
- Preclinical and translational studies of new molecularly targeted agents;
- Innovative immunotherapeutic strategies, including CAR T-cells, bispecific antibodies, and vaccine approaches;
- Approaches to overcoming drug resistance in MM;
- Combination therapies leveraging molecularly targeted agents;
- Biomarkers for patient selection and response prediction;
- Genetic and epigenetic vulnerabilities in myeloma cells.

We welcome original research articles, reviews, and short communications that contribute to our understanding of MM biology and pave the way for next-generation targeted therapies. Join us in advancing the fight against multiple myeloma by submitting your latest findings to this pivotal Special Issue.

---

### Guest Editor

Dr. Daniele Caracciolo

Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy

---

### Deadline for manuscript submissions

26 June 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/249964](https://mdpi.com/si/249964)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)